Jonathan Mizrahi, MD | Ochsner Health

Dr. Jonathan Mizrahi, MD

Claim this profile

Ochsner Medical Center Jefferson

Studies Pancreatic Cancer
Studies Colorectal Cancer
12 reported clinical trials
26 drugs studied

Area of expertise

1Pancreatic Cancer
Jonathan Mizrahi, MD has run 4 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
KRAS positive
NRAS positive
2Colorectal Cancer
Jonathan Mizrahi, MD has run 4 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
KRAS positive
NRAS positive

Affiliated Hospitals

Image of trial facility.
Ochsner Medical Center Jefferson
Image of trial facility.
Ochsner Clinic Foundation

Clinical Trials Jonathan Mizrahi, MD is currently running

Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Image of trial facility.

Perioperative Chemotherapy

for Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Recruiting4 awards Phase 318 criteria

More about Jonathan Mizrahi, MD

Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Jonathan Mizrahi, MD has experience with
  • Fluorouracil
  • Oxaliplatin
  • Capecitabine
  • Leucovorin Calcium
  • Mitomycin
  • Intensity-Modulated Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jonathan Mizrahi, MD specialize in?
Jonathan Mizrahi, MD focuses on Pancreatic Cancer and Colorectal Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are KRAS positive.
Is Jonathan Mizrahi, MD currently recruiting for clinical trials?
Yes, Jonathan Mizrahi, MD is currently recruiting for 4 clinical trials in New Orleans Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Jonathan Mizrahi, MD has studied deeply?
Yes, Jonathan Mizrahi, MD has studied treatments such as Fluorouracil, Oxaliplatin, Capecitabine.
What is the best way to schedule an appointment with Jonathan Mizrahi, MD?
Apply for one of the trials that Jonathan Mizrahi, MD is conducting.
What is the office address of Jonathan Mizrahi, MD?
The office of Jonathan Mizrahi, MD is located at: Ochsner Medical Center Jefferson, New Orleans, Louisiana 70121 United States. This is the address for their practice at the Ochsner Medical Center Jefferson.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security